Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
RET rearrangements are found in 1–2% of non-small-cell lung cancers. Cabozantinib is a multikinase inhibitor with activity against RET that produced a 10% overall response in unselected patients with lung cancers. To assess the activity of cabozantinib in patients with RET-rearranged lung cancers, w...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Drilon, Alexander [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2016 |
|---|
| Umfang: |
8 |
|---|
| Übergeordnetes Werk: |
Enthalten in: My - Citovsky, Vitaly ELSEVIER, 2019, London |
|---|---|
| Übergeordnetes Werk: |
volume:17 ; year:2016 ; number:12 ; pages:1653-1660 ; extent:8 |
| Links: |
|---|
| DOI / URN: |
10.1016/S1470-2045(16)30562-9 |
|---|
| Katalog-ID: |
ELV013752634 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV013752634 | ||
| 003 | DE-627 | ||
| 005 | 20230623110830.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180602s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1470-2045(16)30562-9 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000050A.pica |
| 035 | |a (DE-627)ELV013752634 | ||
| 035 | |a (ELSEVIER)S1470-2045(16)30562-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 570 |q VZ |
| 084 | |a BIODIV |q DE-30 |2 fid | ||
| 084 | |a 35.70 |2 bkl | ||
| 084 | |a 42.12 |2 bkl | ||
| 100 | 1 | |a Drilon, Alexander |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial |
| 264 | 1 | |c 2016 | |
| 300 | |a 8 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a RET rearrangements are found in 1–2% of non-small-cell lung cancers. Cabozantinib is a multikinase inhibitor with activity against RET that produced a 10% overall response in unselected patients with lung cancers. To assess the activity of cabozantinib in patients with RET-rearranged lung cancers, we did a prospective phase 2 trial in this molecular subgroup. | ||
| 700 | 1 | |a Rekhtman, Natasha |4 oth | |
| 700 | 1 | |a Arcila, Maria |4 oth | |
| 700 | 1 | |a Wang, Lu |4 oth | |
| 700 | 1 | |a Ni, Andy |4 oth | |
| 700 | 1 | |a Albano, Melanie |4 oth | |
| 700 | 1 | |a Van Voorthuysen, Martine |4 oth | |
| 700 | 1 | |a Somwar, Romel |4 oth | |
| 700 | 1 | |a Smith, Roger S |4 oth | |
| 700 | 1 | |a Montecalvo, Joseph |4 oth | |
| 700 | 1 | |a Plodkowski, Andrew |4 oth | |
| 700 | 1 | |a Ginsberg, Michelle S |4 oth | |
| 700 | 1 | |a Riely, Gregory J |4 oth | |
| 700 | 1 | |a Rudin, Charles M |4 oth | |
| 700 | 1 | |a Ladanyi, Marc |4 oth | |
| 700 | 1 | |a Kris, Mark G |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n The Lancet Publ. Group |a Citovsky, Vitaly ELSEVIER |t My |d 2019 |g London |w (DE-627)ELV003173852 |
| 773 | 1 | 8 | |g volume:17 |g year:2016 |g number:12 |g pages:1653-1660 |g extent:8 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/S1470-2045(16)30562-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a FID-BIODIV | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 35.70 |j Biochemie: Allgemeines |q VZ |
| 936 | b | k | |a 42.12 |j Biophysik |q VZ |
| 951 | |a AR | ||
| 952 | |d 17 |j 2016 |e 12 |h 1653-1660 |g 8 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
a d ad |
|---|---|
| matchkey_str |
drilonalexanderrekhtmannatashaarcilamari:2016----:aoatnbnainsihdacderarnennmlcllncneaoelblig |
| hierarchy_sort_str |
2016 |
| bklnumber |
35.70 42.12 |
| publishDate |
2016 |
| allfields |
10.1016/S1470-2045(16)30562-9 doi GBV00000000000050A.pica (DE-627)ELV013752634 (ELSEVIER)S1470-2045(16)30562-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Drilon, Alexander verfasserin aut Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial 2016 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier RET rearrangements are found in 1–2% of non-small-cell lung cancers. Cabozantinib is a multikinase inhibitor with activity against RET that produced a 10% overall response in unselected patients with lung cancers. To assess the activity of cabozantinib in patients with RET-rearranged lung cancers, we did a prospective phase 2 trial in this molecular subgroup. Rekhtman, Natasha oth Arcila, Maria oth Wang, Lu oth Ni, Andy oth Albano, Melanie oth Van Voorthuysen, Martine oth Somwar, Romel oth Smith, Roger S oth Montecalvo, Joseph oth Plodkowski, Andrew oth Ginsberg, Michelle S oth Riely, Gregory J oth Rudin, Charles M oth Ladanyi, Marc oth Kris, Mark G oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:17 year:2016 number:12 pages:1653-1660 extent:8 https://doi.org/10.1016/S1470-2045(16)30562-9 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 17 2016 12 1653-1660 8 045F 610 |
| spelling |
10.1016/S1470-2045(16)30562-9 doi GBV00000000000050A.pica (DE-627)ELV013752634 (ELSEVIER)S1470-2045(16)30562-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Drilon, Alexander verfasserin aut Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial 2016 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier RET rearrangements are found in 1–2% of non-small-cell lung cancers. Cabozantinib is a multikinase inhibitor with activity against RET that produced a 10% overall response in unselected patients with lung cancers. To assess the activity of cabozantinib in patients with RET-rearranged lung cancers, we did a prospective phase 2 trial in this molecular subgroup. Rekhtman, Natasha oth Arcila, Maria oth Wang, Lu oth Ni, Andy oth Albano, Melanie oth Van Voorthuysen, Martine oth Somwar, Romel oth Smith, Roger S oth Montecalvo, Joseph oth Plodkowski, Andrew oth Ginsberg, Michelle S oth Riely, Gregory J oth Rudin, Charles M oth Ladanyi, Marc oth Kris, Mark G oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:17 year:2016 number:12 pages:1653-1660 extent:8 https://doi.org/10.1016/S1470-2045(16)30562-9 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 17 2016 12 1653-1660 8 045F 610 |
| allfields_unstemmed |
10.1016/S1470-2045(16)30562-9 doi GBV00000000000050A.pica (DE-627)ELV013752634 (ELSEVIER)S1470-2045(16)30562-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Drilon, Alexander verfasserin aut Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial 2016 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier RET rearrangements are found in 1–2% of non-small-cell lung cancers. Cabozantinib is a multikinase inhibitor with activity against RET that produced a 10% overall response in unselected patients with lung cancers. To assess the activity of cabozantinib in patients with RET-rearranged lung cancers, we did a prospective phase 2 trial in this molecular subgroup. Rekhtman, Natasha oth Arcila, Maria oth Wang, Lu oth Ni, Andy oth Albano, Melanie oth Van Voorthuysen, Martine oth Somwar, Romel oth Smith, Roger S oth Montecalvo, Joseph oth Plodkowski, Andrew oth Ginsberg, Michelle S oth Riely, Gregory J oth Rudin, Charles M oth Ladanyi, Marc oth Kris, Mark G oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:17 year:2016 number:12 pages:1653-1660 extent:8 https://doi.org/10.1016/S1470-2045(16)30562-9 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 17 2016 12 1653-1660 8 045F 610 |
| allfieldsGer |
10.1016/S1470-2045(16)30562-9 doi GBV00000000000050A.pica (DE-627)ELV013752634 (ELSEVIER)S1470-2045(16)30562-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Drilon, Alexander verfasserin aut Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial 2016 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier RET rearrangements are found in 1–2% of non-small-cell lung cancers. Cabozantinib is a multikinase inhibitor with activity against RET that produced a 10% overall response in unselected patients with lung cancers. To assess the activity of cabozantinib in patients with RET-rearranged lung cancers, we did a prospective phase 2 trial in this molecular subgroup. Rekhtman, Natasha oth Arcila, Maria oth Wang, Lu oth Ni, Andy oth Albano, Melanie oth Van Voorthuysen, Martine oth Somwar, Romel oth Smith, Roger S oth Montecalvo, Joseph oth Plodkowski, Andrew oth Ginsberg, Michelle S oth Riely, Gregory J oth Rudin, Charles M oth Ladanyi, Marc oth Kris, Mark G oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:17 year:2016 number:12 pages:1653-1660 extent:8 https://doi.org/10.1016/S1470-2045(16)30562-9 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 17 2016 12 1653-1660 8 045F 610 |
| allfieldsSound |
10.1016/S1470-2045(16)30562-9 doi GBV00000000000050A.pica (DE-627)ELV013752634 (ELSEVIER)S1470-2045(16)30562-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Drilon, Alexander verfasserin aut Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial 2016 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier RET rearrangements are found in 1–2% of non-small-cell lung cancers. Cabozantinib is a multikinase inhibitor with activity against RET that produced a 10% overall response in unselected patients with lung cancers. To assess the activity of cabozantinib in patients with RET-rearranged lung cancers, we did a prospective phase 2 trial in this molecular subgroup. Rekhtman, Natasha oth Arcila, Maria oth Wang, Lu oth Ni, Andy oth Albano, Melanie oth Van Voorthuysen, Martine oth Somwar, Romel oth Smith, Roger S oth Montecalvo, Joseph oth Plodkowski, Andrew oth Ginsberg, Michelle S oth Riely, Gregory J oth Rudin, Charles M oth Ladanyi, Marc oth Kris, Mark G oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:17 year:2016 number:12 pages:1653-1660 extent:8 https://doi.org/10.1016/S1470-2045(16)30562-9 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 17 2016 12 1653-1660 8 045F 610 |
| language |
English |
| source |
Enthalten in My London volume:17 year:2016 number:12 pages:1653-1660 extent:8 |
| sourceStr |
Enthalten in My London volume:17 year:2016 number:12 pages:1653-1660 extent:8 |
| format_phy_str_mv |
Article |
| bklname |
Biochemie: Allgemeines Biophysik |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
My |
| authorswithroles_txt_mv |
Drilon, Alexander @@aut@@ Rekhtman, Natasha @@oth@@ Arcila, Maria @@oth@@ Wang, Lu @@oth@@ Ni, Andy @@oth@@ Albano, Melanie @@oth@@ Van Voorthuysen, Martine @@oth@@ Somwar, Romel @@oth@@ Smith, Roger S @@oth@@ Montecalvo, Joseph @@oth@@ Plodkowski, Andrew @@oth@@ Ginsberg, Michelle S @@oth@@ Riely, Gregory J @@oth@@ Rudin, Charles M @@oth@@ Ladanyi, Marc @@oth@@ Kris, Mark G @@oth@@ |
| publishDateDaySort_date |
2016-01-01T00:00:00Z |
| hierarchy_top_id |
ELV003173852 |
| dewey-sort |
3610 |
| id |
ELV013752634 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV013752634</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623110830.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1470-2045(16)30562-9</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000050A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV013752634</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1470-2045(16)30562-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.70</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Drilon, Alexander</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">RET rearrangements are found in 1–2% of non-small-cell lung cancers. Cabozantinib is a multikinase inhibitor with activity against RET that produced a 10% overall response in unselected patients with lung cancers. To assess the activity of cabozantinib in patients with RET-rearranged lung cancers, we did a prospective phase 2 trial in this molecular subgroup.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rekhtman, Natasha</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Arcila, Maria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wang, Lu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ni, Andy</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Albano, Melanie</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Van Voorthuysen, Martine</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Somwar, Romel</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Smith, Roger S</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Montecalvo, Joseph</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Plodkowski, Andrew</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ginsberg, Michelle S</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Riely, Gregory J</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rudin, Charles M</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ladanyi, Marc</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kris, Mark G</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">The Lancet Publ. Group</subfield><subfield code="a">Citovsky, Vitaly ELSEVIER</subfield><subfield code="t">My</subfield><subfield code="d">2019</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV003173852</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:17</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:12</subfield><subfield code="g">pages:1653-1660</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1470-2045(16)30562-9</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.70</subfield><subfield code="j">Biochemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.12</subfield><subfield code="j">Biophysik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">17</subfield><subfield code="j">2016</subfield><subfield code="e">12</subfield><subfield code="h">1653-1660</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Drilon, Alexander |
| spellingShingle |
Drilon, Alexander ddc 610 ddc 570 fid BIODIV bkl 35.70 bkl 42.12 Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial |
| authorStr |
Drilon, Alexander |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV003173852 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 570 - Life sciences; biology |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial |
| topic |
ddc 610 ddc 570 fid BIODIV bkl 35.70 bkl 42.12 |
| topic_unstemmed |
ddc 610 ddc 570 fid BIODIV bkl 35.70 bkl 42.12 |
| topic_browse |
ddc 610 ddc 570 fid BIODIV bkl 35.70 bkl 42.12 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
n r nr m a ma l w lw a n an m a ma v m v vm vmv r s rs r s s rs rss j m jm a p ap m s g ms msg g j r gj gjr c m r cm cmr m l ml m g k mg mgk |
| hierarchy_parent_title |
My |
| hierarchy_parent_id |
ELV003173852 |
| dewey-tens |
610 - Medicine & health 570 - Life sciences; biology |
| hierarchy_top_title |
My |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV003173852 |
| title |
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial |
| ctrlnum |
(DE-627)ELV013752634 (ELSEVIER)S1470-2045(16)30562-9 |
| title_full |
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial |
| author_sort |
Drilon, Alexander |
| journal |
My |
| journalStr |
My |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2016 |
| contenttype_str_mv |
zzz |
| container_start_page |
1653 |
| author_browse |
Drilon, Alexander |
| container_volume |
17 |
| physical |
8 |
| class |
610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Drilon, Alexander |
| doi_str_mv |
10.1016/S1470-2045(16)30562-9 |
| dewey-full |
610 570 |
| title_sort |
cabozantinib in patients with advanced ret-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial |
| title_auth |
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial |
| abstract |
RET rearrangements are found in 1–2% of non-small-cell lung cancers. Cabozantinib is a multikinase inhibitor with activity against RET that produced a 10% overall response in unselected patients with lung cancers. To assess the activity of cabozantinib in patients with RET-rearranged lung cancers, we did a prospective phase 2 trial in this molecular subgroup. |
| abstractGer |
RET rearrangements are found in 1–2% of non-small-cell lung cancers. Cabozantinib is a multikinase inhibitor with activity against RET that produced a 10% overall response in unselected patients with lung cancers. To assess the activity of cabozantinib in patients with RET-rearranged lung cancers, we did a prospective phase 2 trial in this molecular subgroup. |
| abstract_unstemmed |
RET rearrangements are found in 1–2% of non-small-cell lung cancers. Cabozantinib is a multikinase inhibitor with activity against RET that produced a 10% overall response in unselected patients with lung cancers. To assess the activity of cabozantinib in patients with RET-rearranged lung cancers, we did a prospective phase 2 trial in this molecular subgroup. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA |
| container_issue |
12 |
| title_short |
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial |
| url |
https://doi.org/10.1016/S1470-2045(16)30562-9 |
| remote_bool |
true |
| author2 |
Rekhtman, Natasha Arcila, Maria Wang, Lu Ni, Andy Albano, Melanie Van Voorthuysen, Martine Somwar, Romel Smith, Roger S Montecalvo, Joseph Plodkowski, Andrew Ginsberg, Michelle S Riely, Gregory J Rudin, Charles M Ladanyi, Marc Kris, Mark G |
| author2Str |
Rekhtman, Natasha Arcila, Maria Wang, Lu Ni, Andy Albano, Melanie Van Voorthuysen, Martine Somwar, Romel Smith, Roger S Montecalvo, Joseph Plodkowski, Andrew Ginsberg, Michelle S Riely, Gregory J Rudin, Charles M Ladanyi, Marc Kris, Mark G |
| ppnlink |
ELV003173852 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/S1470-2045(16)30562-9 |
| up_date |
2024-07-06T19:43:32.079Z |
| _version_ |
1803860062585749504 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV013752634</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623110830.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1470-2045(16)30562-9</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000050A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV013752634</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1470-2045(16)30562-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.70</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Drilon, Alexander</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">RET rearrangements are found in 1–2% of non-small-cell lung cancers. Cabozantinib is a multikinase inhibitor with activity against RET that produced a 10% overall response in unselected patients with lung cancers. To assess the activity of cabozantinib in patients with RET-rearranged lung cancers, we did a prospective phase 2 trial in this molecular subgroup.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rekhtman, Natasha</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Arcila, Maria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wang, Lu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ni, Andy</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Albano, Melanie</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Van Voorthuysen, Martine</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Somwar, Romel</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Smith, Roger S</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Montecalvo, Joseph</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Plodkowski, Andrew</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ginsberg, Michelle S</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Riely, Gregory J</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rudin, Charles M</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ladanyi, Marc</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kris, Mark G</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">The Lancet Publ. Group</subfield><subfield code="a">Citovsky, Vitaly ELSEVIER</subfield><subfield code="t">My</subfield><subfield code="d">2019</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV003173852</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:17</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:12</subfield><subfield code="g">pages:1653-1660</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1470-2045(16)30562-9</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.70</subfield><subfield code="j">Biochemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.12</subfield><subfield code="j">Biophysik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">17</subfield><subfield code="j">2016</subfield><subfield code="e">12</subfield><subfield code="h">1653-1660</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.401602 |